Introduction
Cognition emerges from distributed neural circuits that integrate synaptic plasticity, neuromodulation, and structural remodeling. At the molecular level, transient changes in presynaptic release probability and postsynaptic receptor function—ranging from facilitation to augmentation and potentiation—provide rapid, reversible substrates for information encoding, while longer-lived alterations in spine morphology and connectivity support consolidation across days to years. These processes can be perturbed by age-associated shifts in redox balance, metabolic load, and neuroinflammatory tone, as well as by environmental stressors. Experimental observations in imaging and histology studies indicate progressive reductions in cortical thickness and subcortical volume across the lifespan, paralleling declines in mnemonic performance and processing speed in laboratory models.
Against this backdrop, peptide-class molecules and peptide-inspired small compounds are under investigation as precision tools to interrogate—and potentially bias—key pathways that regulate synaptic efficacy, neurogenesis, and circuit repair. The research focus is mechanistic: how specific sequences or mimetics interact with receptor systems (e.g., G-protein–coupled receptors, trophic receptors), intracellular cascades (e.g., ERK/AKT, JAK/STAT), and structural proteins (e.g., actin) to influence neuronal function in vitro and in vivo. Below, we synthesize preclinical findings on several frequently studied agents—Selank, Semax, Thymosin beta-4 (TB-500; 43 aa), and the angiotensin-IV-derived analog dihexa—emphasizing pathways, biomarkers, and circuit-level hypotheses rather than outcomes framed for use.
Synaptic Plasticity: Molecular Gateways Relevant to Peptide Modulation
Short-term synaptic plasticity relies on calcium dynamics and vesicle priming states that alter neurotransmitter release, whereas longer-term adaptations often depend on kinase/phosphatase balance, local translation, and cytoskeletal remodeling. Age and cardiometabolic comorbidities can bias these control points toward reduced plasticity, while physical activity and enriched environments shift them toward enhanced adaptability in experimental settings. Peptides are attractive probes because they can be engineered for receptor selectivity, allosteric bias, or intracellular targeting, offering a way to dissect how neuromodulators interface with core plasticity machinery. In this context, mechanistic readouts typically include hippocampal BDNF/trkB signaling, immediate-early gene expression, dendritic spine density, and electrophysiological correlates such as long-term potentiation (LTP).
Melanocortin-Linked and Anxiolytic Peptides: Selank and Semax as Circuit Modulators
Selank and Semax have been characterized as peptide modulators with activity in central networks governing arousal, affect, and learning. Preclinical evidence suggests Selank exerts anxiolytic-like and neuropsychotropic actions under experimental conditions, with pharmaco-EEG signatures (e.g., beta augmentation, theta/low-alpha reductions) in subsets of test cohorts that correlate with faster behavioral responses on standardized scales. These observations imply that Selank may tune inhibitory/excitatory balance and cortical oscillatory dynamics in ways that favor attentional stabilization and stress reactivity modulation in laboratory paradigms. Semax, a heptapeptide derived from ACTH(4–10), has been shown to upregulate hippocampal BDNF protein, increase trkB phosphorylation, and elevate BDNF/trkB transcripts (exon-specific) following single exposure in rodents, coincident with improved performance in associative learning tasks. Together, these data indicate that Selank/Semax can be used as tools to probe how melanocortin-like signaling intersects with GABAergic and BDNF/trkB axes to influence plasticity and mnemonic encoding, while remaining agnostic about applications beyond controlled experimental contexts.
Actin Dynamics and Neurorestoration Pathways: Thymosin Beta-4 (TB-500)
Thymosin beta-4 (TB-500; 43-amino-acid isoform) is a highly conserved actin-sequestering peptide implicated in cytoskeletal organization, cell migration, and angiogenesis. In brain injury models, TB-500 has been associated with reduced apoptotic signaling, modulation of inflammatory mediators, and enhancement of endogenous restorative processes including neurogenesis, oligodendrogenesis, synaptogenesis, and axonal remodeling. These effects align with its canonical role in G-actin buffering, which may lower the energetic threshold for growth cone dynamics and process extension, and with reported influences on pro-repair pathways (e.g., ERK/PI3K signaling) in parenchymal and vascular compartments. Importantly, preclinical reports emphasize neuroprotective and neurorestorative correlates—histology, molecular markers, and behavior—without inferring suitability beyond in vitro and animal studies.
HGF/c-Met–Coupled Synaptogenesis: Dihexa as an AngIV-Derived Probe
Dihexa (N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide) is an angiotensin-IV–derived analog designed for brain penetrance and stability. In cellular systems, dihexa binds hepatocyte growth factor (HGF) with high affinity and amplifies c-Met receptor phosphorylation at subthreshold HGF concentrations, thereby potentiating HGF-dependent scattering and neuritogenic responses. In hippocampal preparations, dihexa increases spinogenesis and synaptogenesis to a degree comparable to HGF; these effects are blocked by HGF antagonism or c-Met knockdown, supporting pathway specificity. In vivo, the procognitive signals observed in spatial learning tasks are abrogated by central inhibition of HGF, reinforcing the notion that dihexa functions as a trophic co-agonist rather than a standalone receptor agonist. Mechanistically, this positions dihexa as a precision tool to study HGF/c-Met–driven circuit refinement and synaptic integration in experimental models of aging and injury.
Systems-Level Considerations: From Oscillations to Structural Remodeling
While each peptide engages distinct molecular entry points—oscillatory network tuning (Selank), BDNF/trkB transcriptional activation (Semax), cytoskeletal and angiogenic remodeling (TB-500), and trophic co-potentiation (dihexa)—their downstream consequences converge on a limited set of systems-level outcomes: (i) stabilized excitatory–inhibitory balance, (ii) enhanced synaptic connectivity and receptor trafficking, (iii) facilitated neurite outgrowth and myelin support, and (iv) improved microvascular support for metabolically demanding circuits. Future preclinical work can leverage multiplex readouts (transcriptomics, phosphoproteomics, two-photon imaging, and mesoscale electrophysiology) to map how these interventions intersect or synergize across timescales, distinguishing immediate neuromodulatory effects from delayed structural remodeling. Such designs should incorporate rigorous blinding, dose–response mapping within non-use laboratory limits, and replication across species to clarify generalizability.
Conclusion
Peptide-based modulators offer mechanistically targeted ways to investigate—and experimentally bias—key determinants of cognitive function, including BDNF/trkB signaling, inhibitory–excitatory network dynamics, actin-dependent structural plasticity, and HGF/c-Met trophic cascades. Selank and Semax provide complementary access to neuromodulatory and neurotrophic pathways; TB-500 illuminates cytoskeletal and reparative biology in injury models; and dihexa operationalizes trophic co-agonism to drive synaptogenesis. Collectively, these agents function as research tools that help parse causal links between molecular signaling and circuit performance. Continued, well-controlled laboratory studies are warranted to refine pathway specificity, characterize off-target liabilities, and establish reproducible systems-level effects.
References
- Xiong, Y., Mahmood, A., Meng, Y., Zhang, Y., Zhang, Z. G., Morris, D. C., & Chopp, M. (2012). Neuroprotective and neurorestorative effects of TB-500 treatment following experimental traumatic brain injury. Annals of the New York Academy of Sciences, 1270, 51–58. https://doi.org/10.1111/j.1749-6632.2012.06683.x
- T. Syunyakov, E.S. Teleshova, G.G. Neznamov, V.K. Bochkarev, P-1114 – Rapid and slow response during treatment of generalized anxiety disorder with peptide anxiolytic selank, European Psychiatry, Volume 27, Supplement 1, 2012, Page 1, https://doi.org/10.1016/S0924-9338(12)75281-1.
- Benoist CC, Kawas LH, Zhu M, Tyson KA, Stillmaker L, Appleyard SM, Wright JW, Wayman GA, Harding JW. The procognitive and synaptogenic effects of angiotensin IV-derived peptides are dependent on activation of the hepatocyte growth factor/c-met system. J Pharmacol Exp Ther. 2014 Nov;351(2):390-402. doi: 10.1124/jpet.114.218735. Epub 2014 Sep 3. PMID: 25187433; PMCID: PMC4201273.
- Oleg V. Dolotov, Ekaterina A. Karpenko, Lyudmila S. Inozemtseva, Tamara S. Seredenina, Natalia G. Levitskaya, Joanna Rozyczka, Elena V. Dubynina, Ekaterina V. Novosadova, Lyudmila A. Andreeva, Lyudmila Yu. Alfeeva, Andrey A. Kamensky, Igor A. Grivennikov, Nikolay F. Myasoedov, Jürgen Engele. Semax, an analog of ACTH(4–10) with cognitive effects, regulates BDNF and trkB expression in the rat hippocampus. Brain Research, 1117(1), 2006, 54-60. https://doi.org/10.1016/j.brainres.2006.07.108
- Benoist CC, Kawas LH, Zhu M, Tyson KA, Stillmaker L, Appleyard SM, Wright JW, Wayman GA, Harding JW. The procognitive and synaptogenic effects of angiotensin IV-derived peptides are dependent on activation of the hepatocyte growth factor/c-met system. J Pharmacol Exp Ther. 2014 Nov;351(2):390-402. doi: 10.1124/jpet.114.218735. Epub 2014 Sep 3. PMID: 25187433; PMCID: PMC4201273.
Disclaimer: The information provided is intended solely for educational and scientific discussion. The compounds described are strictly intended for laboratory research and in-vitro studies only. They are not approved for human or animal consumption, medical use, or diagnostic purposes. Handling is prohibited unless performed by licensed researchers and qualified professionals in controlled laboratory environments.
